中华肝脏病杂志最新文献_第10页

[Research progress on brucellosis combined with liver injury]. [布鲁氏菌病合并肝损伤的研究进展]。

中华肝脏病杂志 Pub Date : 2025-10-20 DOI: 10.3760/cma.j.cn501113-20250515-00188

Dilnar Ibrahim, X B Lu

引用次数: 0

[Real-time or dynamic non-invasive liver fibrosis testing for evaluating clinical prognoses and predicting chronic liver disease]. [实时或动态无创肝纤维化检测用于评估临床预后和预测慢性肝病]。

中华肝脏病杂志 Pub Date : 2025-10-20 DOI: 10.3760/cma.j.cn501113-20250812-00323

X Y Zhao, Y M Sun, Y K Gao, Z Z Lu, C Huang, Y Y Kong, J D Jia, H You

{"title":"[Real-time or dynamic non-invasive liver fibrosis testing for evaluating clinical prognoses and predicting chronic liver disease].","authors":"X Y Zhao, Y M Sun, Y K Gao, Z Z Lu, C Huang, Y Y Kong, J D Jia, H You","doi":"10.3760/cma.j.cn501113-20250812-00323","DOIUrl":"10.3760/cma.j.cn501113-20250812-00323","url":null,"abstract":"Liver fibrosis is a key histologic marker of long-term outcome in chronic liver disease. Non-invasive tests (NITs) have been shown to have predictive value, but the superiority of \"dynamic\" versus \"static\" assessment remains controversial. This article systematically reviews the latest evidence to elucidate the association between longitudinal changes in NITs and hepatic adverse events and assess the incremental contribution of dynamic monitoring to the model. Additionally, it reveals that the dynamic monitoring of NITs is truly superior to single evaluation, but the evidence is limited and the heterogeneity is significant. Dynamic modeling approaches for NITs require a shift from traditional parameter estimation to time-series machine learning. Future studies should make breakthroughs in disease stratification, modeling method innovation, data quality improvement, and prediction ability assessment so as to promote the transition of NITs from \"static risk label\" to \"dynamic individualized engine,\" which can truly serve clinical decision-making.","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 10","pages":"945-949"},"PeriodicalIF":0.0,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12861841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Advances and challenges in new technologies for imaging evaluation of liver fibrosis]. [肝纤维化影像学评估新技术的进展与挑战]。

中华肝脏病杂志 Pub Date : 2025-10-20 DOI: 10.3760/cma.j.cn501113-20250710-00272

Q C Ge, L G Lu

{"title":"[Advances and challenges in new technologies for imaging evaluation of liver fibrosis].","authors":"Q C Ge, L G Lu","doi":"10.3760/cma.j.cn501113-20250710-00272","DOIUrl":"10.3760/cma.j.cn501113-20250710-00272","url":null,"abstract":"Liver fibrosis is a common pathological process in various chronic liver diseases. Early-stage and accurate diagnosis, as well as assessment of the degree of liver fibrosis, is crucial for the management of chronic liver diseases. Conventional imaging techniques for liver fibrosis (elastography and magnetic resonance elastography) still have the drawback of low sensitivity in detecting early-stage fibrosis. In recent years, emerging imaging omics based on ultrasound and magnetic resonance have improved the diagnostic accuracy and visualization stage of liver fibrosis. The emergence of artificial intelligence technology has also provided more options for the technological advancement of liver fibrosis imaging. This article aims to review the emerging liver fibrosis imaging technologies in recent years and compare their diagnostic performance with ultrasound elastography, shear wave elastography, and magnetic resonance elastography recommended by the current domestic and international guidelines and to pinpoint simultaneously the limitations and challenges that still exist in liver fibrosis imaging while reflecting the technological advances.","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 10","pages":"923-927"},"PeriodicalIF":0.0,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12861862/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Clinical practice and challenges from simple models to precise integration for serological evaluation of a non-invasive diagnosis of liver fibrosis]. [肝纤维化无创诊断血清学评估从简单模型到精确整合的临床实践与挑战]。

中华肝脏病杂志 Pub Date : 2025-10-20 DOI: 10.3760/cma.j.cn501113-20250809-00322

R Jin, W J Ni, F J Rui, J Li

引用次数: 0

[Non-invasive assessment of liver fibrosis: prioritizing dynamic monitoring and expanding population screening]. [无创肝纤维化评估：优先动态监测和扩大人群筛查]。

中华肝脏病杂志 Pub Date : 2025-10-20 DOI: 10.3760/cma.j.cn501113-20250825-00346

P P Lai, S Y Chen, Y M Sun, H You

引用次数: 0

[Research progress on predictive models of portal vein thrombosis in liver cirrhosis]. 肝硬化门静脉血栓形成预测模型研究进展

中华肝脏病杂志 Pub Date : 2025-10-20 DOI: 10.3760/cma.j.cn501113-20241017-00546

Z N Wu, Z Q Qi, Y Xiao, T Y Guo, H Tong, Y D Wang

引用次数: 0

[Chinese guidelines for clinical diagnosis, treatment, and management of cirrhosis (2025)]. [中国肝硬化临床诊断、治疗和管理指南（2025）]。

中华肝脏病杂志 Pub Date : 2025-10-20 DOI: 10.3760/cma.j.cn501113-20250728-00298

引用次数: 0

[Analysis of factors affecting fibrosis reversal in patients with metabolic associated steatohepatitis based on magnetic resonance elastography]. [基于磁共振弹性成像分析代谢相关性脂肪性肝炎患者纤维化逆转的影响因素]。

中华肝脏病杂志 Pub Date : 2025-10-20 DOI: 10.3760/cma.j.cn501113-20250830-00354

Z Y Zhang, C L Sun, H Ren, D W Yang, X Y Zhao, M Y Zhang, X Han, J J Zhao, Q Y Wang, Y M Sun, X Y Zhao, J D Jia, Z H Yang, X F Tong, H You

{"title":"[Analysis of factors affecting fibrosis reversal in patients with metabolic associated steatohepatitis based on magnetic resonance elastography].","authors":"Z Y Zhang, C L Sun, H Ren, D W Yang, X Y Zhao, M Y Zhang, X Han, J J Zhao, Q Y Wang, Y M Sun, X Y Zhao, J D Jia, Z H Yang, X F Tong, H You","doi":"10.3760/cma.j.cn501113-20250830-00354","DOIUrl":"10.3760/cma.j.cn501113-20250830-00354","url":null,"abstract":"Objective: To dynamically assess liver fibrosis using magnetic resonance elastography (MRE) and explore factors associated with fibrosis reversal in patients with metabolic dysfunction-associated steatohepatitis (MASH). Methods: This study included data from patients diagnosed with MASH by liver biopsy who underwent at least two MRE examinations. Patients were divided into a fibrosis reversal group and a non-reversal group according to whether MRE values decreased by 20% during follow-up. Differences in clinical data between the groups were compared using analysis of variance, the Kruskal-Wallis test, and the chi-square test. Univariate and multivariate logistic regression analyses were used to explore independent risk factors for fibrosis reversal in MASH. Results: A total of 46 cases were included in this study (mean age 50.1±12.3 years, BMI 26.1±3.1 kg/m²). Among them, the reversal group accounted for 26.1%. The rate of decrease in MRI proton density fat fraction (PDFF) was significantly higher in the reversal group (-50.0% vs. -8.1%, P=0.001) than in the non-reversal group between the two MRE examinations. The reversal group showed a more significant change rate of decreases in fasting insulin (-37.3% vs. -3.6%, P=0.011), insulin resistance index (-38.6% vs. -6.5%, P=0.044), and ALP (-24.9% vs. 0, P=0.004). Multivariate logistic regression analysis indicated that the rate of change in MRI PDFF was an independent predictor of fibrosis reversal (OR=0.96, 95% CI: 0.92-1.00, P=0.046). Conclusion: A decrease in MRI proton density fat fraction levels is independently associated with liver fibrosis reversal in MASH, suggesting that intervention targeting liver fat content may be an effective treatment strategy.","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 10","pages":"1001-1008"},"PeriodicalIF":0.0,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12861764/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Chinese expert consensus on clinical practice of chronic hepatitis B functional (clinical) cure]. [慢性乙型肝炎功能（临床）治愈临床实践的中国专家共识]。

中华肝脏病杂志 Pub Date : 2025-10-20 DOI: 10.3760/cma.j.cn501113-20250723-00286

引用次数: 0

[How far has non-invasive testing become a surrogate endpoint for the research and development of new drugs for metabolic dysfunction-associated steatohepatitis?] 非侵入性检测在多大程度上已经成为代谢功能障碍相关脂肪性肝炎新药研究和开发的替代终点？]

中华肝脏病杂志 Pub Date : 2025-10-20 DOI: 10.3760/cma.j.cn501113-20250904-00367

Y M Sun, H You

引用次数: 0